标题
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
作者
关键词
-
出版物
LEUKEMIA
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-09-04
DOI
10.1038/s41375-021-01401-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
- (2021) Tiziano Barbui et al. Lancet Haematology
- Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival
- (2021) Ghaith Abu-Zeinah et al. LEUKEMIA
- Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program
- (2021) Alessandro Rambaldi et al. Blood Cancer Journal
- Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
- (2021) Tiziano Barbui et al. LEUKEMIA
- Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication
- (2021) Jordan K. Schaefer et al. JAMA Internal Medicine
- Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis
- (2020) Alberto Alvarez-Larrán et al. ANNALS OF HEMATOLOGY
- Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
- (2020) Lukas Ronner et al. BLOOD
- Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
- (2020) Ayalew Tefferi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm‐associated venous thromboembolism in a large tertiary centre in the UK
- (2020) Natalia Curto‐Garcia et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
- (2020) Heinz Gisslinger et al. Lancet Haematology
- Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis
- (2020) Beatrice Mainoli et al. American Journal of Cardiovascular Drugs
- A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
- (2020) Bianca Rocca et al. BLOOD
- Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study
- (2020) Sylvie Tondeur et al. LEUKEMIA
- Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses
- (2020) Pierre-Edouard Debureaux et al. Blood Advances
- Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management
- (2020) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- A multicenter real‐life study on anticoagulant treatment with direct oral anticoagulants in patients with P h negative myeloproliferative neoplasms
- (2020) Alessandra Serrao et al. AMERICAN JOURNAL OF HEMATOLOGY
- Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis
- (2020) Jan Philipp Bewersdorf et al. LEUKEMIA
- Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management
- (2020) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations
- (2020) Naseema Gangat et al. AMERICAN JOURNAL OF HEMATOLOGY
- Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
- (2020) Karlo Huenerbein et al. ANNALS OF HEMATOLOGY
- Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin
- (2020) Bridget K. Marcellino et al. Blood Advances
- 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
- (2019) Natasha Szuber et al. MAYO CLINIC PROCEEDINGS
- Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis
- (2019) Alberto Ferrari et al. HAEMATOLOGICA
- A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
- (2019) J. Mascarenhas et al. LEUKEMIA
- Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea
- (2019) Abdulraheem Yacoub et al. BLOOD
- Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
- (2019) Emanuela Sant'Antonio et al. AMERICAN JOURNAL OF HEMATOLOGY
- Essential Thrombocythemia
- (2019) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2 V617F mutated disease
- (2018) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pregnancy oucotcome and management of 25 pregnancies in women with polycythemia vera
- (2018) Irene Bertozzi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms
- (2018) Malin Hultcrantz et al. ANNALS OF INTERNAL MEDICINE
- MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
- (2018) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
- (2018) Paola Guglielmelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms
- (2018) Joëlle Lapoirie et al. Journal of Maternal-Fetal & Neonatal Medicine
- Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
- (2018) Maura Nicolosi et al. LEUKEMIA
- Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
- (2018) Ayalew Tefferi et al. LEUKEMIA
- U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
- (2018) Ayalew Tefferi et al. LEUKEMIA
- Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera
- (2018) Tiziano Barbui et al. LEUKEMIA
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
- (2018) Tiziano Barbui et al. LEUKEMIA
- Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis
- (2018) Mads Lamm Larsen et al. PLATELETS
- The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
- (2018) Valerio De Stefano et al. Blood Cancer Journal
- Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data
- (2018) Arianna Ghirardi et al. Blood Cancer Journal
- Polycythemia vera treatment algorithm 2018
- (2018) Ayalew Tefferi et al. Blood Cancer Journal
- Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea
- (2018) Rossella Renso et al. Blood Cancer Journal
- Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger
- (2018) Natasha Szuber et al. AMERICAN JOURNAL OF HEMATOLOGY
- Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features
- (2018) Anna L. Godfrey et al. JOURNAL OF CLINICAL ONCOLOGY
- Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions
- (2018) Florian H. Heidel et al. LEUKEMIA
- Response to “Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions” by Heidel et al.
- (2018) Giovanni Barosi et al. LEUKEMIA
- Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera
- (2018) Tiziano Barbui et al. Blood Cancer Journal
- Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
- (2018) Emmanuelle Verger et al. Blood Cancer Journal
- Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
- (2018) Valerio De Stefano et al. Blood Cancer Journal
- Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates
- (2018) Natasha Szuber et al. Blood Cancer Journal
- Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
- (2017) Guilin Tang et al. HAEMATOLOGICA
- No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials
- (2017) Tiziano Barbui et al. HAEMATOLOGICA
- Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
- (2017) A Tefferi et al. LEUKEMIA
- A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
- (2017) F Passamonti et al. LEUKEMIA
- Genetic Risk Assessment in Myeloproliferative Neoplasms
- (2017) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
- (2017) S. Cerquozzi et al. Blood Cancer Journal
- Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations
- (2017) D Barraco et al. Blood Cancer Journal
- Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
- (2017) Guilin Tang et al. HAEMATOLOGICA
- No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials
- (2017) Tiziano Barbui et al. HAEMATOLOGICA
- Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group
- (2016) Giada Rotunno et al. AMERICAN JOURNAL OF HEMATOLOGY
- The effect of arterial hypertension on thrombosis in low-risk polycythemia vera
- (2016) Tiziano Barbui et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors
- (2016) Brianna E. Vaa et al. ANNALS OF HEMATOLOGY
- Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
- (2016) William Vainchenker et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
- (2016) Alberto Alvarez-Larrán et al. HAEMATOLOGICA
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea
- (2016) Genevieve Douglas et al. LEUKEMIA & LYMPHOMA
- Survival after splanchnic vein thrombosis: A 20-year nationwide cohort study
- (2016) Kirstine Kobberøe Søgaard et al. THROMBOSIS RESEARCH
- Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
- (2016) Alberto Alvarez-Larrán et al. HAEMATOLOGICA
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study
- (2015) T. Barbui et al. BLOOD
- Iron deficiency anemia treatment response to oral iron therapy: a pooled analysis of five randomized controlled trials
- (2015) M. M. Okam et al. HAEMATOLOGICA
- Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study
- (2015) Malin Hultcrantz et al. JOURNAL OF CLINICAL ONCOLOGY
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Iron deficiency anemia treatment response to oral iron therapy: a pooled analysis of five randomized controlled trials
- (2015) M. M. Okam et al. HAEMATOLOGICA
- Long-term Clinical Outcomes of Splanchnic Vein Thrombosis
- (2015) Walter Ageno et al. JAMA Internal Medicine
- Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
- (2014) Alberto Alvarez-Larrán et al. ANNALS OF HEMATOLOGY
- In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
- (2014) T. Barbui et al. BLOOD
- Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
- (2014) G Barosi et al. LEUKEMIA
- Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients
- (2013) Fabian P. Siegel et al. AMERICAN JOURNAL OF HEMATOLOGY
- JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms
- (2013) K. Takahashi et al. BLOOD
- Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon -2a
- (2013) A. Quintas-Cardama et al. BLOOD
- JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
- (2013) E. T. Kuriakose et al. HAEMATOLOGICA
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
- (2013) A Tefferi et al. LEUKEMIA
- Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
- (2012) T. Barbui et al. BLOOD
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
- (2011) F. Passamonti et al. BLOOD
- Mouse models of myeloproliferative neoplasms: JAK of all grades
- (2011) J. Li et al. Disease Models & Mechanisms
- Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera
- (2011) E. Kuriakose et al. HAEMATOLOGICA
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
- (2011) Jean-Jacques Kiladjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria
- (2010) A. Carobbio et al. BLOOD
- Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
- (2010) A. Alvarez-Larran et al. BLOOD
- Polycythemia vera-associated pruritus and its management
- (2010) Kamal S. Saini et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
- (2010) A Pardanani et al. LEUKEMIA
- A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
- (2010) F Passamonti et al. LEUKEMIA
- Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia
- (2009) Valerio De Stefano et al. AMERICAN JOURNAL OF HEMATOLOGY
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera
- (2009) Naseema Gangat et al. CANCER
- Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
- (2008) J.-J. Kiladjian et al. BLOOD
- The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases
- (2008) J.-J. Kiladjian et al. BLOOD
- Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
- (2008) V. De Stefano et al. HAEMATOLOGICA
- Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey
- (2007) M. Ruggeri et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started